Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P040045/S145

VISTAKON (SENOFILCON A) CONTACT LENS, CLEAR AND VISIBILITY TINTED WITH UV BLOCKER

Vistakon, Division of Johnson & Johnson Vision Car · Decision date Sep 2, 2026

MEDTECHLEDGER EXPLANATIONP040045/S145

What did the FDA decide?

FDA recorded a decision dated 2026-09-02 on supplement P040045/S145 to VISTAKON (senofilcon A) contact lens, clear and visibility tinted with UV blocker, held by Vistakon, Division of Johnson & Johnson Vision Car. The supplement is a 30-Day Notice filed under the reason Process Change - Manufacturer/Sterilizer/Packager/Supplier, and the recorded decision code is OK30. The device falls in the soft contact lens, extended wear category, ophthalmic specialty, product code LPM.

The recorded scope is qualification of an existing manufacturing line to produce these lenses at the facility in Jacksonville, Florida. That describes a manufacturing-line change within the existing application rather than a new approval of the lens system as a whole. The public documentation contains no supporting documents and no document record identifier, so the notice contents, the basis for the decision and any conditions attached to it are not available here. Whether OK30 carries a specific administrative meaning is not stated in the source data.

Clinical performance, labeling and patient-selection information are outside this record and remain in the underlying FDA documentation.

FDA approval order statement

qualification of an existing manufacturing line to produce VISTAKON (senofilcon A) contact lenses, at the manufacturing facility located in Jacksonville, Florida
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Ophthalmic
Decision date
Sep 2, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P040045/S145
Regulatory pathway
PMA supplement
Product code
LPM
Decision code
OK30
Decision date
Sep 2, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Lenses, soft contact, extended wear.

Product code
LPM
FDA device class
3

For the original device and its historical approval scope, see PMA P040045. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P040045 · Original PMA

    VISTAKON (SENOFILCON A) CONTACT LENS, CLEAR AND VISIBILITY TINTED WITH UV BLOCKER

  2. P040045/S145 received

    Application receipt date recorded by FDA.

  3. P040045/S145 · FDA decision

    30-Day Notice

  4. P040045/S146 · Related supplement

    VISTAKON (SENOFILCON A) Brand Contact Lenses

  5. P040045/S147 · Related supplement

    VISTAKON (senofilcon A) Brand Contact Lenses

Timeline entries are records held by MedtechLedger for P040045. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P040045

Explore the linked device profile

Other records with product code LPM

Product / regulatory recordCompanyPathwayDecision dateSource
Bausch and Lomb, Inc.,PMA supplementSep 14, 2026FDA
CooperVision, Inc.PMA supplementSep 2, 2026FDA
Bausch and Lomb, Inc.,PMA approvalApr 30, 2018FDA
CooperVision, Inc.PMA approvalNov 19, 2008FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Vistakon, Division of Johnson & Johnson Vision Car

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
7500 Centurion Pkwy., Suite 100 - Erca, Jacksonville, FL, 32256

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records